Cancer Genetics, Inc. (CGIX) Analysts See $-0.11 EPS

March 7, 2018 - By Louis Casey

 Cancer Genetics, Inc. (CGIX) Analysts See $ 0.11 EPS
Investors sentiment decreased to 0.57 in Q3 2017. Its down 0.60, from 1.17 in 2017Q2. It fall, as 5 investors sold Cancer Genetics, Inc. shares while 9 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.58 million shares or 6.28% less from 2.76 million shares in 2017Q2 were reported.
Two Sigma Securities Llc reported 14,616 shares. Granahan Inv Mngmt Incorporated Ma, a Massachusetts-based fund reported 237,431 shares. Wells Fargo And Company Mn reported 15,823 shares or 0% of all its holdings. Next Financial Gp accumulated 2,500 shares or 0% of the stock. Renaissance Technologies Ltd Com holds 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX) for 569,400 shares. Hrt Finance Ltd Llc owns 15,301 shares or 0.05% of their US portfolio. Perkins invested 2.28% in Cancer Genetics, Inc. (NASDAQ:CGIX). Blackrock holds 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX) for 40,734 shares. Moreover, Thompson Davis Incorporated has 0.22% invested in Cancer Genetics, Inc. (NASDAQ:CGIX) for 46,975 shares. 1,342 were accumulated by Tower Research Cap Limited Liability Com (Trc). Northern Trust Corporation reported 34,771 shares. The Ontario – Canada-based Royal State Bank Of Canada has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). New York-based Virtu Limited Liability Corp has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). 486,850 are owned by Vanguard Group. North Carolina-based Financial Bank Of America De has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX).

Since December 15, 2017, it had 1 insider buy, and 0 sales for $24,339 activity.

Analysts expect Cancer Genetics, Inc. (NASDAQ:CGIX) to report $-0.11 EPS on March, 22.They anticipate $0.04 EPS change or 26.67 % from last quarter’s $-0.15 EPS. After having $-0.16 EPS previously, Cancer Genetics, Inc.’s analysts see -31.25 % EPS growth. The stock increased 5.29% or $0.09 during the last trading session, reaching $1.79. About 14,642 shares traded. Cancer Genetics, Inc. (NASDAQ:CGIX) has risen 81.82% since March 7, 2017 and is uptrending. It has outperformed by 65.12% the S&P500.

Cancer Genetics, Inc. (NASDAQ:CGIX) Ratings Coverage

Among 7 analysts covering Cancer Genetics (NASDAQ:CGIX), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Cancer Genetics had 11 analyst reports since March 11, 2016 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Tuesday, August 15 with “Buy”. H.C. Wainwright maintained it with “Buy” rating and $6.0 target in Tuesday, February 6 report. On Thursday, December 7 the stock rating was initiated by Maxim Group with “Buy”. The company was maintained on Thursday, September 21 by H.C. Wainwright. The stock has “Neutral” rating by Janney Capital on Friday, March 11. H.C. Wainwright maintained the shares of CGIX in report on Tuesday, January 16 with “Buy” rating. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, November 29. Rodman & Renshaw initiated the shares of CGIX in report on Monday, September 26 with “Buy” rating. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) has “Buy” rating given on Tuesday, March 15 by Aegis Capital.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $43.41 million. The Company’s tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

Another recent and important Cancer Genetics, Inc. (NASDAQ:CGIX) news was published by which published an article titled: “FDA Clears 23AndMe’s DTC Breast Cancer Gene Test — But ‘Buyer Beware'” on March 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: